Kalcoral kit150 mg+600 mg+400 IU

Kalcoral kit is a combination product used in the management of osteoporosis, combining a bisphosphonate with calcium and vitamin D3 supplementation to support bone mineralization during anti-resorptive therapy.

Established / Guideline-Supported Uses

• Treatment of postmenopausal osteoporosis - to increase bone mineral density and reduce the risk of vertebral fractures, with the calcium and vitamin D3 component supplied as an adjunct to ensure adequate mineral substrate for bone formation.
• Prevention of postmenopausal osteoporosis in women at increased risk of bone loss (e.g. early postmenopausal women with low bone mass).

Adjunct / Supportive Use

• The calcium carbonate [coral source] and vitamin D3 component is used to correct or prevent calcium and vitamin D insufficiency, which is required before and during bisphosphonate therapy for the bisphosphonate to work safely and effectively.

Kalcoral kit is not indicated for prevention or treatment of osteoporosis in men or for glucocorticoid-induced osteoporosis unless specifically advised by a physician, as robust evidence for these uses with this specific combination is limited.

Each Ibandronic Acid + Calcium Carbonate [Coral source] + Vitamin D3 pack typically contains two components dispensed on an alternating schedule:

• Ibandronic Acid 150 mg (as ibandronate sodium) - one tablet taken once monthly.
• Calcium Carbonate [Coral source] equivalent to elemental Calcium 500 mg, combined with Vitamin D3 (Cholecalciferol) 200 IU - one tablet taken once daily on the remaining days of the month.

The coral-source calcium carbonate is a naturally derived form of calcium carbonate; its elemental calcium content and clinical effect are equivalent to other pharmaceutical-grade calcium carbonate sources.

Kalcoral kit is a fixed combination regimen pairing a nitrogen-containing bisphosphonate (ibandronic acid) with calcium carbonate (derived from a coral source) and vitamin D3. It is designed for the management of osteoporosis, where the bisphosphonate slows bone loss by inhibiting osteoclast activity, while the calcium and vitamin D3 component ensures the mineral and hormonal substrate needed for normal bone remodeling and to reduce the risk of treatment-related hypocalcemia.

Because oral bisphosphonates and calcium compete for absorption and must be dosed separately, Kalcoral kit is supplied so that the ibandronic acid tablet is taken once monthly under strict administration conditions, while the calcium carbonate [coral source] plus vitamin D3 tablet is taken daily on the other days of the month with food.

Kalcoral kit belongs to the bisphosphonate (anti-resorptive bone agent) class combined with a calcium and vitamin D3 supplement, used together in the therapeutic management of osteoporosis.

Ibandronic Acid + Calcium Carbonate [Coral source] + Vitamin D3 combines agents with complementary mechanisms in bone metabolism:

Ibandronic Acid

Ibandronic acid is a nitrogen-containing bisphosphonate that binds avidly to hydroxyapatite crystals in bone, with preferential uptake at sites of active bone remodeling. It is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast cytoskeletal function and promoting osteoclast apoptosis. This reduces bone resorption, allowing bone formation to outpace resorption and increasing bone mineral density over time.

Calcium Carbonate [Coral source]

Calcium carbonate dissociates in the acidic environment of the stomach to release elemental calcium, which is absorbed in the small intestine and used to maintain the calcium pool required for bone mineralization and to prevent bisphosphonate-associated hypocalcemia.

Vitamin D3 (Cholecalciferol)

Vitamin D3 is hydroxylated in the liver and kidney to its active form, which increases intestinal absorption of calcium and phosphate and supports normal bone mineralization, working synergistically with the calcium component and enabling the anti-resorptive effect of ibandronic acid.

The ibandronic acid tablet in Kalcoral kit must be taken on an empty stomach with plain water only, first thing in the morning, followed by at least 60 minutes upright and fasting; the calcium carbonate [coral source] plus vitamin D3 tablet should be taken with food on the alternate days, several hours apart from the ibandronic acid dose.

Clinically significant interactions relevant to Kalcoral kit include:

• Calcium, antacids, and other multivalent cation products (magnesium, iron, aluminum): Markedly reduce absorption of the ibandronic acid component if taken together. This is the reason the calcium/vitamin D3 tablet in Kalcoral kit is scheduled on separate days from the bisphosphonate tablet; any additional calcium-containing products, antacids, or mineral supplements should be separated from the ibandronic acid dose by at least 60 minutes (and preferably longer).
• Oral bisphosphonates or other agents with similar esophageal irritant potential: Concurrent use with other bisphosphonates should be avoided due to additive risk of esophageal and upper gastrointestinal irritation.
• NSAIDs and aspirin: May increase the risk of gastrointestinal irritation when combined with the ibandronic acid component; use with caution.
• Thiazide diuretics: Can reduce urinary calcium excretion and increase the risk of hypercalcemia when combined with the calcium carbonate [coral source] component; calcium levels should be monitored.
• Tetracycline or fluoroquinolone antibiotics, levothyroxine, and bisphosphonate-class or iron-containing medicines: Absorption of these agents can be reduced by the calcium component of Kalcoral kit; separate dosing by several hours.

Side effects associated with Kalcoral kit reflect both its bisphosphonate and calcium/vitamin D3 components.

Common

• Upper gastrointestinal upset - heartburn, dyspepsia, abdominal pain, nausea
• Constipation or, less commonly, diarrhea
• Musculoskeletal pain (back pain, myalgia, arthralgia)
• Headache
• Mild flu-like symptoms (more common after the first dose, especially with intravenous bisphosphonate forms)

Less Common but Serious

• Esophagitis, esophageal ulceration, or esophageal erosion - see Precautions and Warnings for the strict dosing instructions that reduce this risk.
• Osteonecrosis of the jaw - see Precautions and Warnings.
• Atypical femur fractures with long-term bisphosphonate use - see Precautions and Warnings.
• Hypercalcemia or milk-alkali syndrome with excessive calcium/vitamin D intake.
• Hypersensitivity reactions, including rare severe skin reactions.

Kalcoral kit is not recommended for use in women who are pregnant, may become pregnant, or are breastfeeding. The bisphosphonate component is not indicated for use in premenopausal women; bisphosphonates are incorporated into bone and released slowly over years, and the potential effect on a fetus from maternal bone-released bisphosphonate during a future pregnancy has not been fully characterized. Use only if clearly needed and if the potential benefit justifies the potential risk to the fetus or infant; a physician should be consulted before use in this setting.

The calcium carbonate [coral source] and vitamin D3 component, at recommended supplemental doses, is generally considered acceptable in pregnancy and lactation, but total intake from all sources (diet, prenatal vitamins, and this product) should be reviewed by a physician to avoid excessive calcium or vitamin D intake.

The following precautions apply to Kalcoral kit:

• Osteonecrosis of the jaw (ONJ): Reported with bisphosphonate therapy, more frequently with invasive dental procedures, cancer, chemotherapy, corticosteroid use, or poor oral hygiene. A dental examination and any necessary preventive dentistry should be completed before starting the ibandronic acid component of Kalcoral kit. Patients should maintain good oral hygiene and inform their dentist that they are taking Kalcoral kit before any invasive dental procedure.
• Atypical femur fractures: Long-term bisphosphonate use has been associated with rare atypical subtrochanteric and femoral shaft fractures, sometimes bilateral. New or unusual thigh, hip, or groin pain should be evaluated promptly, and periodic reassessment of the need for continued bisphosphonate therapy is recommended (see Duration of Treatment).
• Esophageal and upper gastrointestinal irritation: Strict administration instructions (full glass of plain water, remaining upright for at least 60 minutes, taking on a fully empty stomach) must be followed to reduce the risk of esophagitis, esophageal ulcer, or erosion. Patients who cannot comply with these instructions should not take the ibandronic acid component.
• Hypocalcemia: Must be corrected before starting therapy; calcium and vitamin D status should be adequate throughout treatment, which is the purpose of the accompanying calcium carbonate [coral source] and vitamin D3 tablets.
• Renal function: Should be assessed before and periodically during treatment, as the bisphosphonate component is renally cleared.
• Hypercalcemia / milk-alkali syndrome: Avoid additional calcium or antacid intake beyond what is recommended, particularly in patients with impaired renal function.

Overdose of the ibandronic acid component of Kalcoral kit may cause hypocalcemia, hypophosphatemia, and upper gastrointestinal irritation (esophagitis, gastritis, ulcer); overdose of the calcium carbonate/vitamin D3 component may cause hypercalcemia (nausea, vomiting, constipation, confusion, abnormal heart rhythm) or, with chronic excess, vitamin D toxicity.

In case of suspected overdose of Kalcoral kit, seek immediate medical attention or contact emergency services / a poison control center. Do not attempt to induce vomiting. Milk or antacids may be given to bind the bisphosphonate if oral overdose has just occurred and the patient can remain upright, but definitive management, including monitoring of serum calcium and renal function, should be provided by a physician in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: The ibandronic acid component of Kalcoral kit requires caution in mild-to-moderate renal impairment and is contraindicated in severe renal impairment (see Contraindications); the calcium/vitamin D3 component should also be used cautiously in renal impairment because of the risk of hypercalcemia.

Hepatic impairment: No dose adjustment is generally required, as ibandronic acid is not significantly metabolized by the liver; specific data are limited, so use with medical supervision.

Elderly: No overall dose adjustment is required based on age alone; elderly patients are more likely to have reduced renal function, so renal status should be assessed.

Pediatric use: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation.

Duration of therapy with Kalcoral kit is individualized. The bisphosphonate component is typically continued for several years as guided by fracture risk and bone density response; because of the small but real risk of atypical femur fractures and osteonecrosis of the jaw with prolonged use, physicians commonly reassess the need for continued bisphosphonate therapy after approximately 3-5 years (a "drug holiday" may be considered in lower-risk patients). The calcium carbonate [coral source] and vitamin D3 component is generally continued for as long as the bisphosphonate is used, and often longer, to maintain bone health.

Bisphosphonates (nitrogen-containing); Calcium supplements; Vitamin D analogs (cholecalciferol)

Ibandronic Acid + Calcium Carbonate [Coral source] + Vitamin D3 works through two complementary mechanisms: the ibandronic acid component inhibits osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in osteoclasts, promoting osteoclast apoptosis and slowing bone turnover, while the calcium carbonate [coral source] and vitamin D3 component increases intestinal calcium absorption and supplies the mineral substrate needed for normal bone mineralization, supporting the net gain in bone mineral density achieved with anti-resorptive therapy.

C

Safety and efficacy of the ibandronic acid component of Kalcoral kit have not been established in pediatric patients, and it is not indicated for use in children or adolescents. Osteoporosis requiring bisphosphonate therapy is uncommon in this age group and should be managed only by a specialist when used at all. The calcium carbonate and vitamin D3 component alone may be used in children for calcium/vitamin D supplementation under medical guidance, but Kalcoral kit as a combination product is intended for adult use.